[go: up one dir, main page]

ECSP22034515A - FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7 - Google Patents

FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7

Info

Publication number
ECSP22034515A
ECSP22034515A ECSENADI202234515A ECDI202234515A ECSP22034515A EC SP22034515 A ECSP22034515 A EC SP22034515A EC SENADI202234515 A ECSENADI202234515 A EC SENADI202234515A EC DI202234515 A ECDI202234515 A EC DI202234515A EC SP22034515 A ECSP22034515 A EC SP22034515A
Authority
EC
Ecuador
Prior art keywords
formulations
antibody
antibodies
retard
amino acid
Prior art date
Application number
ECSENADI202234515A
Other languages
English (en)
Inventor
Willow Diluzio
Vaithianathan Palaniappan
Nobel T Truong
Irving H Fox
Csanad M Varga
Jason Brown
Catherine Scholz
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP22034515(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ECSP22034515A publication Critical patent/ECSP22034515A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Endocrinology (AREA)

Abstract

Se describen formulaciones de anticuerpo que comprenden una mezcla de un azúcar no reductor, anticuerpo anti-alfa4beta7 y al menos un aminoácido. Las formulaciones descritas tienen una estabilidad mejorada, una formación de agregados reducida y pueden retrasar la degradación del anticuerpo anti-47 en las mismas o presentar cualquier combinación de las mismas.
ECSENADI202234515A 2011-05-02 2022-04-29 FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7 ECSP22034515A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481533P 2011-05-02 2011-05-02
US201161550545P 2011-10-24 2011-10-24
US201261585859P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
ECSP22034515A true ECSP22034515A (es) 2022-05-31

Family

ID=46085207

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSP13013050 ECSP13013050A (es) 2011-05-02 2013-11-26 Formulación para anticuerpo anti- 4 7
ECSENADI202234515A ECSP22034515A (es) 2011-05-02 2022-04-29 FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSP13013050 ECSP13013050A (es) 2011-05-02 2013-11-26 Formulación para anticuerpo anti- 4 7

Country Status (42)

Country Link
US (15) US9764033B2 (es)
EP (4) EP2704798B1 (es)
JP (7) JP6190360B2 (es)
KR (8) KR20250094743A (es)
CN (4) CN108079291B (es)
AR (1) AR086237A1 (es)
AU (7) AU2012250873B2 (es)
BR (1) BR112013028424A2 (es)
CA (2) CA3028209C (es)
CL (2) CL2013003146A1 (es)
CO (1) CO6801647A2 (es)
CR (1) CR20130677A (es)
CY (1) CY1119435T1 (es)
DK (2) DK2704798T3 (es)
DO (1) DOP2013000253A (es)
EA (1) EA032729B1 (es)
EC (2) ECSP13013050A (es)
ES (2) ES3016382T3 (es)
FI (1) FI3329965T3 (es)
GE (1) GEP201706734B (es)
HK (1) HK1249466A1 (es)
HR (2) HRP20171432T1 (es)
HU (2) HUE036663T2 (es)
IL (5) IL275038B2 (es)
LT (2) LT3329965T (es)
MA (1) MA35136B1 (es)
ME (1) ME02859B (es)
MX (4) MX348814B (es)
MY (2) MY172735A (es)
PE (2) PE20190405A1 (es)
PH (3) PH12013502236A1 (es)
PL (2) PL2704798T3 (es)
PT (2) PT3329965T (es)
RS (2) RS66809B1 (es)
SG (1) SG194652A1 (es)
SI (2) SI3329965T1 (es)
SM (2) SMT201700508T1 (es)
TW (3) TWI664980B (es)
UA (2) UA116189C2 (es)
UY (1) UY34053A (es)
WO (1) WO2012151248A2 (es)
ZA (3) ZA201308069B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
CN108969761A (zh) 2011-05-02 2018-12-11 米伦纽姆医药公司 抗α4β7抗体的制剂
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112014007852B1 (pt) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc Polinucleotídeo isolado modificado e composição farmacêutica
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
TW201945032A (zh) * 2013-03-15 2019-12-01 德商艾伯維德國有限及兩合公司 抗-egfr抗體藥物結合物調配物
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
ES2910443T3 (es) * 2014-04-16 2022-05-12 Biocon Ltd Formulaciones de proteínas estables que comprenden un exceso molar de sorbitol
US10532051B2 (en) * 2014-10-06 2020-01-14 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodies
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3237004B1 (en) * 2014-12-24 2024-05-08 Takeda Pharmaceutical Company Limited Predicting outcome of treatment with an anti-alpha4 beta7 integrin antibody
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
US10654931B2 (en) * 2015-08-11 2020-05-19 Osaka University Antibody
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
US20200002422A1 (en) * 2016-03-14 2020-01-02 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
EP3430053A1 (en) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
WO2017158393A1 (en) * 2016-03-18 2017-09-21 Oslo University Hospital Hf Methods of treating graft-versus-host disease
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
ES2962373T3 (es) * 2016-04-13 2024-03-18 Medimmune Llc Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas
JP7162533B2 (ja) 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法
US11389533B2 (en) 2016-06-12 2022-07-19 Takeda Pharmaceutical Company Limited Method of treating inflammatory bowel disease
WO2018068012A1 (en) * 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
HRP20220550T1 (hr) * 2016-12-23 2022-06-10 Immunogen, Inc. Imunokonjugati koji ciljaju adam9 i postupci njihove uporabe
KR20190141148A (ko) * 2017-04-28 2019-12-23 밀레니엄 파머슈티컬스 인코퍼레이티드 소아 장애를 치료하는 방법
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
JP7497159B2 (ja) * 2017-05-26 2024-06-10 ミレニアム ファーマシューティカルズ， インコーポレイテッド 慢性回腸嚢炎の治療のための方法
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
IL322968A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical treatment
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3773695A4 (en) * 2018-04-10 2021-12-22 Dr. Reddy's Laboratories Ltd. STABLE ANTIBODY FORMULATION
US12433947B2 (en) 2018-04-10 2025-10-07 Dr. Reddy's Laboratories Limited Stable formulations of therapeutic antibody
EP3773694A4 (en) * 2018-04-10 2021-12-29 Dr. Reddy's Laboratories Ltd. Antibody formulation
AU2019277632A1 (en) 2018-05-31 2020-12-24 National Cancer Center Japan Biomarker for judging efficacy of immune checkpoint inhibitor
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CN109239335A (zh) * 2018-09-11 2019-01-18 广州万孚生物技术股份有限公司 联检试纸条及其制备方法
WO2020123241A1 (en) * 2018-12-10 2020-06-18 Clear Creek Bio, Inc. Multiphasic dosing regimens for treating cancer
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
WO2020215019A1 (en) * 2019-04-17 2020-10-22 Millennium Pharmaceuticals, Inc. Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
PL439809A1 (pl) * 2019-06-10 2022-12-05 Takeda Pharmaceutical Company Limited Metody wytwarzania przeciwciała anty-alfa4beta7
MX2021015301A (es) * 2019-06-10 2022-02-03 Takeda Pharmaceuticals Co Métodos de cultivo celular y composiciones para la producción de anticuerpos.
CA3143169A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Antibody purification methods and compositions thereof
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN113577281A (zh) * 2020-04-30 2021-11-02 中国科学院分子细胞科学卓越创新中心 调控整合素β亚基的试剂和方法
UY39327A (es) 2020-07-16 2022-02-25 Abbvie Inc Anticuerpos anti- alpha-4-beta-7
EP4281045A4 (en) * 2021-01-20 2024-12-18 Dr. Reddy's Laboratories Limited LYOPHILIZED ANTIBODY FORMULATIONS AND RELATED METHODS
CN117545501A (zh) * 2021-05-07 2024-02-09 雷迪博士实验室有限公司 改善抗体制剂的稳定性的方法
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025133872A1 (en) * 2023-12-19 2025-06-26 Intas Pharmaceuticals Ltd. Method for reducing oxidation levels in vedolizumab during cell culture process
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods
US20260016226A1 (en) * 2024-07-14 2026-01-15 Frei Jonathan Advanced lyophilization control interfaces and techniques
US20260015407A1 (en) 2024-07-15 2026-01-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory fusion proteins and related methods

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US774216A (en) 1903-11-19 1904-11-08 Alexander F Ward Machine for pointing and lapping hoops.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
EP0303463B1 (en) 1987-08-11 1994-11-30 The Board Of Trustees Of The Leland Stanford Junior University Method to control leukocyte extravasation
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
WO1990007321A2 (en) 1988-12-23 1990-07-12 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte receptor homing sequences and their uses
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69233153T2 (de) 1991-03-06 2004-05-27 Merck Patent Gmbh Humanisierte monoklonale antikörper
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
JPH07506566A (ja) 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
AU5732694A (en) 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
WO1994013312A1 (en) 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
AU687790B2 (en) 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
EP0804237B8 (en) 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
WO1996024673A1 (en) 1995-02-10 1996-08-15 Leukosite, Inc. Mucosal vascular addressins and uses thereof
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
IL163725A0 (en) * 2002-02-25 2005-12-18 Elan Pharm Inc Administration of agents for the treatment of inflammation
CA2485681C (en) 2002-05-24 2012-10-16 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
ATE363470T1 (de) 2002-11-18 2007-06-15 Chemocentryx Inc Arylsulfonamide
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
HUE028441T2 (hu) 2004-09-03 2016-12-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
AU2006316629A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
MX2009003635A (es) 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
PE20080857A1 (es) 2006-10-20 2008-08-19 Amgen Inc Formulaciones a base de polipeptidos estables
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
CA2671968A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
MX2010001488A (es) * 2007-08-08 2010-03-01 Abbott Lab Composiciones y metodos para cristalizar anticuerpos.
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
MX2011009897A (es) 2009-03-20 2011-12-08 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
AU2010263058A1 (en) * 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
CN108969761A (zh) 2011-05-02 2018-12-11 米伦纽姆医药公司 抗α4β7抗体的制剂
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3224280A1 (en) * 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3237004B1 (en) 2014-12-24 2024-05-08 Takeda Pharmaceutical Company Limited Predicting outcome of treatment with an anti-alpha4 beta7 integrin antibody
JP7162533B2 (ja) 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法

Also Published As

Publication number Publication date
KR20200035503A (ko) 2020-04-03
CA2834867A1 (en) 2012-11-08
US20180207279A1 (en) 2018-07-26
US20250288679A1 (en) 2025-09-18
CN103608071B (zh) 2017-12-26
US20160340432A1 (en) 2016-11-24
AU2016231469B2 (en) 2018-12-20
AU2019201926A1 (en) 2019-04-11
CN108187042A (zh) 2018-06-22
EP3329965A1 (en) 2018-06-06
PE20141175A1 (es) 2014-09-25
AU2016231469A1 (en) 2016-10-06
JP7492057B2 (ja) 2024-05-28
KR102465394B1 (ko) 2022-11-09
EP4378484A3 (en) 2024-09-04
US12053526B2 (en) 2024-08-06
US9764033B2 (en) 2017-09-19
AR086237A1 (es) 2013-11-27
SMT202500218T1 (it) 2025-07-22
CN108079291A (zh) 2018-05-29
KR102275603B1 (ko) 2021-07-08
JP7258941B2 (ja) 2023-04-17
JP6878489B2 (ja) 2021-05-26
PE20190405A1 (es) 2019-03-14
TWI664980B (zh) 2019-07-11
DK2704798T3 (en) 2017-10-23
US20190231878A1 (en) 2019-08-01
PL2704798T3 (pl) 2017-12-29
EP3329965B1 (en) 2025-03-19
MA35136B1 (fr) 2014-05-02
JP2024098027A (ja) 2024-07-19
SMT201700508T1 (it) 2017-11-15
EP2704798A2 (en) 2014-03-12
HK1256106A1 (en) 2019-09-13
DOP2013000253A (es) 2013-12-31
US20140377251A1 (en) 2014-12-25
CL2013003146A1 (es) 2014-07-25
US20190076532A1 (en) 2019-03-14
ZA201806946B (en) 2022-03-30
PH12018500030B1 (en) 2022-05-04
SI3329965T1 (sl) 2025-07-31
JP2017137351A (ja) 2017-08-10
RS56397B1 (sr) 2017-12-29
IL296838A (en) 2022-11-01
US20180289811A1 (en) 2018-10-11
ECSP13013050A (es) 2014-01-31
WO2012151248A2 (en) 2012-11-08
IL275038B (en) 2022-11-01
IL267668B (en) 2020-10-29
US20250295786A1 (en) 2025-09-25
SI2704798T1 (sl) 2017-12-29
AU2018278866A1 (en) 2019-01-03
IL275038B2 (en) 2023-03-01
JP6534415B2 (ja) 2019-06-26
LT2704798T (lt) 2017-10-25
CR20130677A (es) 2014-10-07
PT2704798T (pt) 2017-11-14
JP6473845B2 (ja) 2019-02-20
PL3329965T3 (pl) 2025-04-28
US20210052733A1 (en) 2021-02-25
KR20180127540A (ko) 2018-11-28
MY172735A (en) 2019-12-11
TWI664978B (zh) 2019-07-11
MX356827B (es) 2018-06-15
JP2014514346A (ja) 2014-06-19
PH12013502236A1 (en) 2014-01-06
HRP20250472T1 (hr) 2025-06-06
US20250000981A1 (en) 2025-01-02
PH12018500030A1 (en) 2018-10-15
PT3329965T (pt) 2025-04-02
US20170002078A1 (en) 2017-01-05
EP3263178A1 (en) 2018-01-03
JP2018150388A (ja) 2018-09-27
TW201247223A (en) 2012-12-01
HK1249466A1 (en) 2018-11-02
ES2645187T3 (es) 2017-12-04
IL229104A0 (en) 2013-12-31
MY183471A (en) 2021-02-19
KR20140145953A (ko) 2014-12-24
RS66809B1 (sr) 2025-06-30
HRP20171432T1 (hr) 2017-11-03
BR112013028424A2 (pt) 2021-05-04
JP2023076616A (ja) 2023-06-01
AU2012250873A1 (en) 2013-05-09
US9663579B2 (en) 2017-05-30
WO2012151248A3 (en) 2013-02-28
UA116189C2 (uk) 2018-02-26
TW201718012A (zh) 2017-06-01
EA201391614A1 (ru) 2014-07-30
HUE036663T2 (hu) 2018-07-30
AU2018278866B2 (en) 2020-07-09
CY1119435T1 (el) 2018-03-07
MX2021006723A (es) 2022-05-03
CN108079291B (zh) 2022-04-08
PH12020500336A1 (en) 2021-02-22
EP3329965A3 (en) 2018-12-12
CN108129565A (zh) 2018-06-08
JP2019108400A (ja) 2019-07-04
CO6801647A2 (es) 2013-11-29
ZA201707158B (en) 2019-01-30
SG194652A1 (en) 2013-12-30
AU2025202434A1 (en) 2025-04-24
IL267668A (en) 2019-08-29
ME02859B (me) 2018-04-20
ES3016382T3 (en) 2025-05-09
FI3329965T3 (fi) 2025-04-30
KR20170116217A (ko) 2017-10-18
JP2021113223A (ja) 2021-08-05
CN103608071A (zh) 2014-02-26
NZ617833A (en) 2016-04-29
AU2020250249B2 (en) 2022-10-06
KR20210084711A (ko) 2021-07-07
MX383317B (es) 2025-03-13
KR101923378B1 (ko) 2018-11-29
KR20220154834A (ko) 2022-11-22
KR20250094743A (ko) 2025-06-25
KR102096484B1 (ko) 2020-04-02
GEP201706734B (en) 2017-09-25
IL296847A (en) 2022-11-01
CN108129565B (zh) 2022-09-20
JP6190360B2 (ja) 2017-08-30
US20200206353A1 (en) 2020-07-02
CA3028209C (en) 2021-01-05
EA032729B1 (ru) 2019-07-31
US10004808B2 (en) 2018-06-26
HUE071510T2 (hu) 2025-09-28
EP2704798B1 (en) 2017-07-12
TWI556828B (zh) 2016-11-11
US12171832B2 (en) 2024-12-24
US20120282249A1 (en) 2012-11-08
LT3329965T (lt) 2025-06-10
KR101923371B1 (ko) 2018-11-29
US20220370617A1 (en) 2022-11-24
TW201906631A (zh) 2019-02-16
DK3329965T3 (da) 2025-04-07
MX348814B (es) 2017-06-30
AU2022231726A1 (en) 2022-10-06
CA2834867C (en) 2019-02-12
KR20180050435A (ko) 2018-05-14
IL275038A (en) 2020-07-30
UA126545C2 (uk) 2022-11-02
US10143752B2 (en) 2018-12-04
AU2020250249A1 (en) 2020-11-05
UY34053A (es) 2012-11-30
US20250041424A1 (en) 2025-02-06
CL2017000830A1 (es) 2017-12-22
MX2013012724A (es) 2013-12-06
ZA201308069B (en) 2016-01-27
AU2022231726B2 (en) 2025-01-09
CA3028209A1 (en) 2012-11-08
AU2012250873B2 (en) 2016-07-07
US20160340431A1 (en) 2016-11-24
EP4378484A2 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
ECSP22034515A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
ECSP22046340A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
BR112012029912A2 (pt) vácinas de combinação de nanotransportadores sintéticos
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
GT201400111A (es) Triazolopiridinas sustituidas
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
BR112013030554A2 (pt) forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
UA111098C2 (uk) Проліки адреномедуліну на основі поліетиленгліколю і їх застосування
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
EA201400447A1 (ru) АНТИТЕЛА К CD1d
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
BR112014009950A2 (pt) composto dissubstituído, compostos e composição farmacêutica
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
BR112013031575A2 (pt) composto peptídico ciclado de estrutura principal, composição farmacêutica, uso de composto, e, processo para a manufatura de um composto.
BR112013008749A2 (pt) análogos de ciclosporina
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
ES2415029A8 (es) Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24.
EA201400444A1 (ru) Производные 2-оксопиперидинила